Titre :

Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance

Auteur(s) :

Laurent, Camille [Auteur]
Trisal, Preeti [Auteur]
Tesson, Bruno [Auteur]
Seth, Sahil [Auteur]
Beyou, Alicia [Auteur]
Roulland, Sandrine [Auteur]
Lesne, Bastien [Auteur]
Van Acker, Nathalie [Auteur]
Cerapio, Juan-Pablo [Auteur]
Chartier, Loïc [Auteur]
Guille, Arnaud [Auteur]
Stokes, Matthew E. [Auteur]
Huang, C. Chris [Auteur]
Huet, Sarah [Auteur]
Gandhi, Anita K. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Service d'Hématologie Cellulaire [Lille]
Xerri, Luc [Auteur]

Titre de la revue :

Blood

Nom court de la revue :

Blood

Numéro :

144

Pagination :

2503–2516

Éditeur :

American Society of Hematology

Date de publication :

2024-12-12

ISSN :

1528-0020

Mot(s)-clé(s) en anglais :

Clinical Trials and Observations
Lymphoid Neoplasia

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy ...
Lire la suite >A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy (R-chemo) or rituximab-lenalidomide (R2) were analyzed using RNA sequencing, DNA sequencing, immunohistochemistry (IHC), and/or fluorescence in situ hybridization. Unsupervised gene clustering identified 2 gene expression signatures (GSs) enriched in normal memory (MEM) B cells and germinal center (GC) B-cell signals, respectively. These 2 GSs were combined into a 20-gene predictor (FL20) to classify patients into MEM-like (n = 160) or GC-like (n = 164) subtypes, which also displayed different mutational profiles. In the R-chemo arm, patients with MEM-like FL had significantly shorter progression-free survival (PFS) than patients with GC-like FL (hazard ratio [HR], 2.13; P = .0023). In the R2 arm, both subtypes had comparable PFS, demonstrating that R2 has a benefit over R-chemo for patients with MEM-like FL (HR, 0.54; P = .011). The prognostic value of FL20 was validated in an independent FL cohort with R-chemo treatment (GSE119214 [n = 137]). An IHC algorithm (FLcm) that used FOXP1, LMO2, CD22, and MUM1 antibodies was developed with significant prognostic correlation with FL20. These data indicate that FL tumors can be classified into MEM-like and GC-like subtypes that are biologically distinct and clinically different in their risk profile. The FLcm assay can be used in routine clinical practice to identify patients with MEM-like FL who might benefit from therapies other than R-chemo, such as the R2 combination. This trial was registered at www.clinicaltrials.gov as #NCT01476787 and #NCT01650701.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Date de dépôt :

2024-12-08T22:05:24Z
2024-12-20T10:36:19Z